1531634-31-7 Usage
Uses
Used in Pharmaceutical Industry:
AF38469 is used as a therapeutic agent for the treatment of autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, and type 1 diabetes. Its ability to suppress the activity of effector memory T cells makes it a promising candidate for managing the pathogenesis of these conditions.
Used in Research and Development:
AF38469 is used as a research tool for studying the role of the Kv1.3 potassium channel in T cell function. Its specificity for this channel inhibition aids in understanding the mechanisms underlying T cell activation and proliferation, which is crucial for developing novel treatment strategies for autoimmune disorders.
Used in Drug Discovery and Development:
AF38469 is utilized in the development of new drugs targeting the Kv1.3 potassium channel. Its selectivity and potency make it a valuable lead compound for designing and optimizing therapeutic agents that can modulate T cell activity and potentially treat autoimmune diseases more effectively.
Check Digit Verification of cas no
The CAS Registry Mumber 1531634-31-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,5,3,1,6,3 and 4 respectively; the second part has 2 digits, 3 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1531634-31:
(9*1)+(8*5)+(7*3)+(6*1)+(5*6)+(4*3)+(3*4)+(2*3)+(1*1)=137
137 % 10 = 7
So 1531634-31-7 is a valid CAS Registry Number.
1531634-31-7Relevant academic research and scientific papers
N-SUBSTITUTED-5-SUBSTITUTED PHTHALAMIC ACIDS AS SORTILIN INHIBITORS
-
Page/Page column 64-65, (2015/02/06)
The present invention is directed to N-substituted-5-substituted phthalamic acids which of formula (A). The compounds are considered useful for the treatment of diseases treatment of a neurodegenerative disease, psychiatric disease, motorneuron disease, peripheral neuropathies, pain, neuroinflammation or atherosclerosis such as Alzheimer's disease and Parkinson's disease.
The identification of AF38469: An orally bioavailable inhibitor of the VPS10P family sorting receptor Sortilin
Schroder, Tenna Juul,Christensen, Soren,Lindberg, Samsa,Langgard, Morten,David, Laurent,Maltas, Philip J.,Eskildsen, Jorgen,Jacobsen, Jan,Tagmose, Lena,Simonsen, Klaus Baek,Biilmann Ronn, Lars Christian,De Jong, Inge E.M.,Malik, Ibrahim J.,Karlsson, Jens-Jakob,Bundgaard, Christoffer,Egebjerg, Jan,Stavenhagen, Jeffrey B.,Strandbygard, Dorthe,Thirup, Soren,Andersen, Jacob Lauwring,Uppalanchi, Srinivas,Pervaram, Sridhar,Kasturi, Shiva Prasad,Eradi, Pradheep,Sakumudi, Durga Rao,Watson, Stephen P.
, p. 177 - 180 (2014/01/17)
The identification of the novel, selective, orally bioavailable Sortilin inhibitor AF38469 is described. Structure-activity relationships and syntheses are reported, along with an X-ray crystal structure of the sortilin-AF38469 protein-inhibitor complex.
